ArticleHelicobacter
Antimicrobial Resistance Profile of Helicobacter pylori in Shenzhen, China: A Retrospective Study From 2021 to 2024.
Article in Helicobacter. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe escalating antibiotic resistance of Helicobacter pylori (H. pylori) poses a significant threat to global public health. Continuous local surveillance is crucial due to substantial geographical and temporal variations in resistance patterns.
objectiveThis study aimed to characterize the antimicrobial resistance profile of H. pylori in Shenzhen, China, between 2021 and 2024, and to assess temporal trends and demographic associations.
methodsWe conducted a retrospective analysis of patients who underwent gastroscopy at Shenzhen Hospital of Southern Medical University from March 2021 to October 2024. Gastric mucosal biopsies were collected for H. pylori culture, and antimicrobial susceptibility testing was performed using the agar dilution method.
resultsAmong culture-positive isolates, 225 were from treatment-naïve patients and 975 from previously treated patients. Resistance rates in the treatment-naïve vs. previously treated groups were: clarithromycin 17.8% vs. 68.0%, metronidazole 87.1% vs. 97.4%, levofloxacin 11.1% vs. 50.9%, amoxicillin 0.4% vs. 3.1%, and furazolidone 0% vs. 0.1%. No tetracycline-resistant isolates were identified. Significant temporal increases were observed in secondary resistance to clarithromycin, amoxicillin, and metronidazole, as well as in the prevalence of multidrug resistance (all p < 0.05). No sex-based differences were detected in either primary or secondary resistance rates (all p > 0.05). Secondary resistance to clarithromycin, metronidazole, and levofloxacin varied significantly across age groups (p < 0.05), whereas primary resistance rates did not.
conclusionsBetween 2021 and 2024, H. pylori isolates in Shenzhen exhibited high resistance rates to metronidazole, clarithromycin, and levofloxacin, while susceptibility to amoxicillin, furazolidone, and tetracycline remained preserved. Secondary resistance rates increased progressively over time, accompanied by a growing burden of multidrug resistance. Bismuth-containing quadruple therapy and high-dose dual therapy are recommended as first-line empirical regimens for treatment-naïve patients, whereas susceptibility-guided therapy is warranted for those with prior treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.